Article Information
Published By
Online ISSN
History
- Received September 19, 2022
- Accepted September 30, 2022
- Published online October 27, 2022.
Article Versions
- You are currently viewing a previous version of this article (October 27, 2022 - 06:16).
- View the most recent version of this article
Copyright & Usage
Copyright ©The authors 2022 This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions@ersnet.org
Author Information
- Laurits Frøssing1,6⇑,
- Ditte K Klein1,6,
- Morten Hvidtfeldt1,
- Nicolai Obling2,
- Gunilla Telg3,
- Jonas S Erjefält4,
- Uffe Bodtger2,5 and
- Celeste Porsbjerg1
- 1Respiratory Research Unit, Department of Respiratory Medicine, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Denmark
- 2Respiratory Research Unit PLUZ, Department of Respiratory Medicine; Zealand University Hospital Naestved, Denmark
- 3Astrazeneca Nordic, Södertälje, Sweden
- 4Unit of Airway Inflammation, Lund University, Sweden
- 5Institute of Regional Health Research, University of Southern Denmark, Denmark
- 6Contributed equally
- Corresponding author: Laurits Frøssing (froessing{at}dadlnet.dk)
Funding
Teva Pharmaceutical Industries
Unrestricted grantInterreg Öresund-Kattegat-Skagerrak
NYPS20201002AstraZeneca
Unrestricted grant
Article usage
Altmetrics
Vol 9 Issue 6
Table of Contents
Distribution of Type 2 biomarkers and association with severity, clinical characteristics and co-morbidities in the BREATHE real-life asthma population
